42 Amendments of Dan NICA related to 2018/0225(COD)
Amendment 240 #
Proposal for a decision
Recital 5 a (new)
Recital 5 a (new)
(5 a) Horizon Europe gives high importance to the links between inclusive societies, R&I and societal challenges. The gender dimension is crucial to design inclusive societies as well as to produce responsible R&I, and constitutes a societal challenge in itself as stated in the UN Sustainable Development Goals. Gender impact should be addressed in any social and industrial transformation. This requires ensuring that gender will be appropriately integrated in all the instruments of Horizon Europe, from pillars, misions, clusters or international cooperation, to open science and open data.
Amendment 259 #
Proposal for a decision
Recital 7 a (new)
Recital 7 a (new)
(7 a) Our future is intimately linked to the future of the seas, oceans and coasts. The seas, oceans and coasts provide multiple ecosystem services and a wealth of resources, influence climate and provide many economic opportunities. The concept Blue Economy (every economic activity associated to oceans, seas, ports and coastal areas) was defined by the European Commission in its report in September 2012 Communication from the Commission: Blue Growth opportunities for marine and maritime sustainable growth. Horizon Europe will give special attention to activities related to the Blue Economy in all pillars with special focus on clusters ‘Food and Natural Resources'.
Amendment 279 #
Proposal for a decision
Article 2 – paragraph 2 – point a a (new)
Article 2 – paragraph 2 – point a a (new)
(a a) widening participation in the Programme, including underrepresented EU Member States and EU R&I institutions
Amendment 334 #
Proposal for a decision
Article 2 – paragraph 2 – point k a (new)
Article 2 – paragraph 2 – point k a (new)
(k a) translating research outcomes into meaningful, tangible benefits for citizens;
Amendment 341 #
Proposal for a decision
Article 2 – paragraph 2 – point m a (new)
Article 2 – paragraph 2 – point m a (new)
(m a) accelerating the transition towards a green, sustainable and decarbonised European industry and society;
Amendment 364 #
Proposal for a decision
Article 3 – paragraph 1 – point 2 – introductory part
Article 3 – paragraph 1 – point 2 – introductory part
(2) Pillar II 'GlobSocietal Challenges and Industrial Competitiveness' with the following components:
Amendment 373 #
Proposal for a decision
Article 3 – paragraph 1 – point 2 – point b
Article 3 – paragraph 1 – point 2 – point b
(b) cluster 'Inclusive and Secure Society', as described in Annex I, Pillar II, section 2;
Amendment 376 #
Proposal for a decision
Article 3 – paragraph 1 – point 2 – point b a (new)
Article 3 – paragraph 1 – point 2 – point b a (new)
(b a) cluster 'Secure Society', as described in Annex I, Pillar II, section 2a;
Amendment 420 #
Proposal for a decision
Article 4 – paragraph 1
Article 4 – paragraph 1
1. In accordance with Article 9(1)of Regulation … FP/RfP Regulation, the financial envelope for the implementation of the Specific Programme for the period 2021 to 2027 shall be EUR 94 1120 000 000 000 in current prices.
Amendment 424 #
Proposal for a decision
Article 5 – paragraph 1 – introductory part
Article 5 – paragraph 1 – introductory part
1. For each mission, a mission board may be established for co-designing and steering implementation. It shall be composed of around 1528 high level individuals including relevant end-users' representatives. The mission board shall cover a balanced geographical distribution and include, inter alia, representatives from academia, research and technology organisations, industry of all sizes, territorial authorities, and relevant end-users' representatives. The members of the mission board shall be appointed by the Commission, following an independent and transparent procedure for their selection, including an open call for expressions of interest. They shall advise upon the following:
Amendment 510 #
Proposal for a decision
Article 10 – paragraph 3 – subparagraph 1
Article 10 – paragraph 3 – subparagraph 1
The EIC Board shall cover a balanced geographical and gender distribution and shall be composed of 15 to 2028 high level individuals drawn from various parts of Europe's innovation ecosystem, including entrepreneurs, corporate leaders, investors and researchers. It shall contribute to outreach actions, with EIC Board members striving to enhance the prestige of the EIC brand.
Amendment 522 #
Proposal for a decision
Article 10 – paragraph 3 – subparagraph 3 a (new)
Article 10 – paragraph 3 – subparagraph 3 a (new)
The European Parliament shall be informed and consulted before the appointment of the President and the members of the EIC Board.
Amendment 529 #
Proposal for a decision
Article 10 – paragraph 5
Article 10 – paragraph 5
5. A code of conduct addressing, inter alia, the avoidance of conflict of interests shall be established by the Commission. Members of the EIC Board are expected to accept the code of conduct upon assuming office, and shall be dismissed in case a conflict of interests arises.
Amendment 590 #
Proposal for a decision
Annex I – paragraph 9
Annex I – paragraph 9
In the 'GlobSocietal Challenges and Industrial Competitiveness' and the 'Open Innovation' Pillars, research and innovation will be complemented with activities which operate close to the end-users and the market, such as demonstration, piloting or proof-of-concept, excluding however commercialisation activities going beyond the research and innovation phase. This will also include support to demand-side activities that help accelerate the deployment and diffusion of a broad range of innovations. Emphasis will be put on non-prescriptive calls for proposals.
Amendment 595 #
Proposal for a decision
Annex I – paragraph 10
Annex I – paragraph 10
Under the 'GlobSocietal Challenges and Industrial Competitiveness' pillar, building on experience in Horizon 2020, the social sciences and the humanities will be fully integrated across all clusters, including specific and dedicated activities. Likewise, activities involving marine and maritime research and innovation will be implemented in a strategic and integrated manner in line with the EU Integrated Maritime Policy, the Common Fisheries Policy Policies and international commitments.
Amendment 603 #
Proposal for a decision
Annex I – paragraph 13
Annex I – paragraph 13
While the European Institute of Innovation and Technology's (EIT) focus on innovation ecosystems makes it naturally fit within the Open Innovation pillar of Horizon Europe, the planning of the EIT Knowledge and Innovation Communities (KICs) will be aligned through the Strategic Planning process with the GlobSocietal Challenges and Industrial Competitiveness pillar.
Amendment 693 #
Proposal for a decision
Annex I – part I – point 3 – point 3.1 – paragraph 2
Annex I – part I – point 3 – point 3.1 – paragraph 2
The overall aim is to endow Europe with world-class sustainable research infrastructures open and accessible to all researchers in Europe and beyond, which fully exploit their potential for scientific advance and innovation. Key objectives are to reduce the fragmentation of the research and innovation ecosystem, avoiding duplication of effort, and better coordinate the development and use of research infrastructures everywhere in the Union . It is crucial to support open access to research infrastructures for all European researchers as well as, through the European Open Science Cloud (hereafter 'EOSC'), increased access to digital research resources, specifically tackling the currently sub-optimal embracement of open science and open data practises. Equally, the EU needs to tackle the rapid increase of global competition for talent by attracting third country researchers to work with European world-class research infrastructures. Increasing the competitiveness of European industry is also a major objective, supporting key technologies and services relevant for research infrastructures and their users, thus improving the conditions for supply of innovative solutions.
Amendment 718 #
Proposal for a decision
Annex I – part II – title
Annex I – part II – title
II SOCIETAL CHALLENGES AND INDUSTRIAL COMPETITIVENESS
Amendment 729 #
Proposal for a decision
Annex I – part II – paragraph 3
Annex I – part II – paragraph 3
Research and innovation are key drivers of sustainable development, including sustainable growth and industrial competitiveness, and they will contribute to finding solutions to today’s problems, to reverse as quickly as possible, the negative and dangerous trend that currently links economic development, the use of natural resources and social issues, and turn it into new business opportunities.
Amendment 745 #
Proposal for a decision
Annex I – part II – paragraph 6 a (new)
Annex I – part II – paragraph 6 a (new)
The role of fundamental research but also the contribution from the whole spectrum of research disciplines, including Social Sciences and Humanities (SSH), will be central to the call definition. The clusters will contribute to the development of knowledge-based learning societies and the achievement of societal progress.
Amendment 754 #
Proposal for a decision
Annex I – part II – point 1 – point 1.1 – paragraph 2 a (new)
Annex I – part II – point 1 – point 1.1 – paragraph 2 a (new)
Health research provides the knowledge basis for more healthy people and for better patient care. Health research has unique features, connecting and interacting closely with innovation, patient care and population health, and operating in a multidisciplinary environment with complex regulations. Health research delivers societal value beyond financial return and is primary concern of European citizens.
Amendment 798 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.1 – paragraph 2 – indent 6 a (new)
Annex I – part II – point 1 – point 1.2 – point 1.2.1 – paragraph 2 – indent 6 a (new)
- Pediatric diseases;
Amendment 813 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.2 – paragraph 2 – indent 1
Annex I – part II – point 1 – point 1.2 – point 1.2.2 – paragraph 2 – indent 1
– TechnologiesSafe, effective, affordable etchnologies, including low-cost technologies, for assessing hazards, exposures and health impact of chemicals, pollutants and other stressors, including climate-related and environmental stressors, and combined effects of several stressors;
Amendment 836 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.3 – paragraph 2 – indent 4
Annex I – part II – point 1 – point 1.2 – point 1.2.3 – paragraph 2 – indent 4
– TSuitable, safe, effective and affordable treatments or cures, including both pharmacological and nonpharmacological treatments;
Amendment 846 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 1
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 1
– Drivers for the emergence or re- emergence of infectious diseases and their spread, including transmission mechanisms from animals to humans (zoonosis), or from other parts of the environment (water, soil, plants, food) to humans and the implementation of empirical preventative solutions that minimize transmission;
Amendment 849 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 2 a (new)
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 2 a (new)
- Development of new antibiotics to combat superbacteria.
Amendment 853 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 3
– VSuitable, safe, effective and affordable vaccines, diagnostics, treatments and cures for infectious diseases, including co-morbidities and co- infections;
Amendment 860 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
Annex I – part II – point 1 – point 1.2 – point 1.2.4 – paragraph 2 – indent 6
– Trans-border aspects of infectious diseases and specific challenges in low- and middle-income countries (LMICs), such as tropical diseasesin particular poverty-related diseases, such as neglected tropical diseases, AIDS, tuberculosis and malaria.
Amendment 900 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.6 – paragraph 2 – indent 4 a (new)
Annex I – part II – point 1 – point 1.2 – point 1.2.6 – paragraph 2 – indent 4 a (new)
- Equity in service access and health outcomes;
Amendment 906 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.6 a (new)
Annex I – part II – point 1 – point 1.2 – point 1.2.6 a (new)
1.2.6 a. Cancer Cancer accounts for a quarter of all deaths and is the number one cause of death for people aged 45-64 in an increasing number of Member States overtaking cardiovascular disease.In 2012 it was estimated that 14.1 million new cases were diagnosed worldwise and more than 8.2 million people died from cancer, making it one of the major health issues1a. In recognition of this development, global research efforts to fight cancer have been ongoing since the 1970's to turn this disease into a chronic, instead of a fatal one.This goal represents a formidable challenge for researchers and clinicians alike.Cancer is a complex disease caused by interactions of multiple factors, such as genetic predisposition, environmental and lifestyle influences, infectious agents and ageing.The past years have witnessed a dramatic progress in understanding the molecular mechanisms at work in the transformation of a normal cell into a cancer cell.Yet, knowledge is still far from complete and much remains to be discovered. Intensive collaboration among scientific, medical, technological and pharmaceutical communities is thus indispensable.Therefore, collaborative research on cancer has been a high priority in the EU framework programmes and remains a key priority in Horizon Europe. Broad Lines – Molecular Oncology with a focus on the study of some of the most active areas of research in cellular oncology, including DNA and chromosome stability, oncogenes and cell cycle kinases, DNA replication, mitosis, tumour suppressors, molecular mechanisms in melanoma, metabolism and cell signalling, and metastasis. – Structural Biology to use structural information to provide mechanistic understanding how proteins and macromolecular complexes related to cancer function at a molecular level and to use the new mechanistic insights to help guide future drug design. – Cancer Cell Biology to achieve a better understanding of the events leading to cancer development, progression and metastasis, and to discover molecular mechanisms that could provide a basis for novel therapies. – Genetics, genomics, pharmacogenetics, molecular cytogenetics and the environmental bases of human cancer. – Biotechnology namely Genomics, Proteomics, Monoclonal Antibodies, Histopathology, Flow Cytometry, Confocal Microscopy, Molecular Imaging and Transgenic Mice. – Experimental therapies and the application of early drug discovery phases in order to obtain advanced compounds ready for in vivo Proof of Concept studies. – Clinical Research to develop novel agents, to study the mechanisms of action of novel compounds and tackling drug resistance ;and to move forward in the field of biomarkers, functional taxonomy and precision medicine. – Pediatric cancer. _________________ 1a https://www.cancerresearchuk.org/health- professional/cancer-statistics/worldwide- cancer#heading-One
Amendment 907 #
Proposal for a decision
Annex I – part II – point 1 – point 1.2 – point 1.2.6 b (new)
Annex I – part II – point 1 – point 1.2 – point 1.2.6 b (new)
1.2.6 b. Cardiovascular disease - CVD Across Europe, both between and within countries, wealthier people live longer, healthier lives than poorest Europeans.There is a difference of at least 11 years between the lowest and the highest average life expectancy in EU countries.Cardiovascular disease is still the main cause of death in the EU, mainly in women.It costs 210 billion euro to the EU in annual costs of which, 102 billion euro are for diet-related CVD.CVD needs therefore a strong focus within Horizon Europe.Poor diet is a leading contributor to ill/health disease.Of all the risk factors related to behaviour that contribute to cardiovascular diseases, dietary factors are by far the largest.Dietary risks are responsible for 56% and 49% of all the years lost to cardiovascular death or disability in the European region and EU respectively. Broad Lines – Molecular pathology of the arterial thrombosis.Molecular pathology of atherosclerosis illness. – Heart rate and contraction. – Myocardial damage and its consequences. – Arterial pathology, myocardial ischemia and structural pathology of the heart. – Molecular and imaging biomarkers, and precision cardiovascular medicine. – Heart diseases related to social, economic and health services inequalities and nutrition and dietary factors. – Sustainable food systems for cardiovascular health and food- environment related to cardiovascular diseases. – Cardiovascular epidemiology and risk factors cardiovascular epidemiology and risk factors. – Genetic of cardiovascular diseases.Expression genes regulation involved in the vascular lesion.Regulation and functional genomic.Nutrition and obesity. – Neovascularization impact in the metastasis processes.Tissue factor.Angiogenesis in the atherosclerotic plaque. – Cellular restructuring and cellular cardiomyoplasty.Functional and phenotypic characterization of differential cellules into heart cell and from myoblastic or from mother cells.Modified cells cellular following through fluorescent probes. Angiogenesis. – Diagnostic and prognostic markers of cardiovascular disease. Serum proteomic differential. Differential proteomic of vascular cellules with emphasis in secreted cellular products.
Amendment 1348 #
Proposal for a decision
Annex I – part II – point 4 – point 4.2 – point 4.2.2 – paragraph 1
Annex I – part II – point 4 – point 4.2 – point 4.2.2 – paragraph 1
The EU aims to be world leader in affordable, secure and sustainable energy technologies improving its competitiveness in global value chains and its position in growth markets. Diverse climatic, geographical, environmental and socio- economic conditions in the EU as well as the need to ensure energy security and access to raw materials, dictate a broad portfolio of energy solutions, including of non-technical nature. As regards renewable energy technologies, costs need to decrease further, persignificant improvements need to be made on system integration. The energy transition will challenge the EU to lead in developing solutions form ance must improve, integration into the energy system must be improved and upgraded market design including the provision of grid and system services by variable renewables. This is needed to make the most of renewable energy solutions. To achieve the necessary deployment levels of clean energy technologies, costs need to decrease further and performance must improve which requires support for incremental research in advanced technologies. In addition, new breakthrough technologies need to be developed. As regards fossil fuels, decarbonising their usage will be essential to meet the climate objectives.
Amendment 1371 #
Proposal for a decision
Annex I – part II – point 4 – point 4.2 – point 4.2.2 – paragraph 2 – indent 2 a (new)
Annex I – part II – point 4 – point 4.2 – point 4.2.2 – paragraph 2 – indent 2 a (new)
- Next generation technology solutions, including the development of new materials, manufacturing processes and operations methods to increase industrial competitiveness in clean energy technology;
Amendment 1621 #
Proposal for a decision
Annex I – part II – point 5 – point 5.2 – point 5.2.4 – paragraph 2 – indent 1 b (new)
Annex I – part II – point 5 – point 5.2 – point 5.2.4 – paragraph 2 – indent 1 b (new)
- Developing new bio products based on marine organisms, with a wide range of applications opening new products and services opportunities.
Amendment 1922 #
Proposal for a decision
Annex I – part 4 – point 1 – introductory part
Annex I – part 4 – point 1 – introductory part
1. SHARPREADING EXCELLENCE33 _________________ 33 innovation excellence will be used to define those Member States and Associated Countries where legal entities need to be established in order to be eligible to submit proposals as coordinators under 'sharing excellence'. This criterion will address the dimensions of the overall economic performance (GDP), research performance and innovation performance in a combined manner normalised to the size of the related countries. The countries identified with this criterion are called 'eligible countries' in the context of 'sharing excellence'. On the basis of Article 349 TFEU, legal entities from Outermost Regions will be also fully eligible as coordinators under 'sharing excellence'. AND WIDENING PARTICIPATION A criterion based on research and
Amendment 1926 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 1
Annex I – part 4 – point 1 – paragraph 1
Reducing disparities in research and innovation performance by sharing knowledge and expertise across the EU and by widening participation in the Programme will help both countries and regions that are lagging behind in terms of research and innovation performance, including the EU outermost regions, to attain a competitive position in the global value chains and the Union to fully benefit from R&I potential of all Member States. Activities may also be established to foster brain circulation right across ERA and better exploitation of existing (and possibly jointly managed EU programmes) research infrastructures in the targeted countries through mobility and collaboration of researchers and innovators and setting new R&I networks and R&I initiatives on the base of those infrastructures.
Amendment 1928 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 1 a (new)
Annex I – part 4 – point 1 – paragraph 1 a (new)
Legal entities need to be established in those EU Members States, which are ranked below 70% of the EU27 average of the composite indicator on Research Excellence implemented under Horizon 2020 in order to be eligible to submit proposals as coordinators under 'spreading excellence and widening participation'. The countries identified with this criterion are called 'eligible countries' in the context of 'spreading excellence and widening participation'.
Amendment 1930 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 3 – indent 1
Annex I – part 4 – point 1 – paragraph 3 – indent 1
– Teaming, to create new centres of excellence or upgrade existing ones in eligible countries, building on partnerships, including through new excellent research and innovation activities, in eligible countries, building on cooperation in all stages of research between leading scientific institutions and partner institutions;
Amendment 1932 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 3 – indent 2
Annex I – part 4 – point 1 – paragraph 3 – indent 2
– Twinning, to significantly strengthen a university or research organisation from an eligible country in a defined field, in all stages of research, by linking it with internationally-leading research institutions or research initiatives from other Member States or Associated Countries.
Amendment 1934 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 3 – indent 3 b (new)
Annex I – part 4 – point 1 – paragraph 3 – indent 3 b (new)
- - “Excellence for EU infrastructures”, to support creation new excellent research and innovation networks or new centres of excellence on the base of research infrastructures financed from ERDF in ‘spreading excellence and widening participation’ eligible countries, to boost new R&I cooperation patterns across Europe and involve those infrastructures in excellent collaborative projects, aiming synergies between national and regional R&I strategies and the Programme.
Amendment 1935 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 3 – indent 3 c (new)
Annex I – part 4 – point 1 – paragraph 3 – indent 3 c (new)
Amendment 1941 #
Proposal for a decision
Annex I – part 4 – point 1 – paragraph 5
Annex I – part 4 – point 1 – paragraph 5
This intervention areae ‘Spreading excellence and widening participation’ priority will support the Horizon Europe specific objectives: Sspread and connect excellence across the EU and widen participation in the Programme, including underperforming Member States; Reinforce the creation of high quality knowledge; Increase cross- sectorial, cross- disciplinary cross-border cooperation. and boost creation of the new R&I activities and networks, involving widening eligible countries and excellent ‘newcomers’ from EU Member States; Support ‘Science and citizens’ activities